11 results found.

Open Angle Glaucoma, or Ocular Hypertension Clinical Trial using PG324 Ophthalmic Solution, 0.01%; PG324 Ophthalmic Solution, 0.02%; AR-13324 Ophthalmic Solution, 0.02%; Latanoprost Ophthalmic Solution, 0.005%

Aerie Pharmaceuticals - Recruiting 18 years or older.
- A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solution, 0.005% in Patients With Elevated Intraocular Pressure.
PG324 Ophthalmic Solution, 0.01%; PG324 Ophthalmic Solution, 0.02%; AR-13324 Ophthalmic Solution, 0.02%; Latanoprost Ophthalmic Solution, 0.005%

Glaucoma, or Ocular Hypertension Clinical Trial using bimatoprost 0.01% ophthalmic solution; bimatoprost 0.03% ophthalmic solution

Allergan - Recruiting 18 years or older.
- .
bimatoprost 0.01% ophthalmic solution; bimatoprost 0.03% ophthalmic solution

Ocular Hypertension, or Open-Angle Glaucoma Clinical Trial using Latanoprost Punctal Plug Delivery System (L-PPDS); Timolol Maleate GFS, 0.5%

Mati Therapeutics Inc. - Recruiting 18 years or older.
- A Phase 2 Single-Masked, Randomized, Parallel Comparison of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Timolol Maleate Ophthalmic Gel Forming Solution 0.5% in Subjects With Ocular Hypertension or Open-Angle Glaucoma.
Latanoprost Punctal Plug Delivery System (L-PPDS); Timolol Maleate GFS, 0.5%

Glaucoma, or Ocular Hypertension Clinical Trial using bimatoprost 0.01%; travatan 0.004%; timolol 0.5%; hypromellose 0.3%

Allergan - Recruiting 18 years or older.
- .
bimatoprost 0.01%; travatan 0.004%; timolol 0.5%; hypromellose 0.3%

Glaucoma, or Ocular Hypertension Clinical Trial using Bimatoprost 0.01%; Bimatoprost 0.03%

Allergan - Recruiting 18 years or older.
- .
Bimatoprost 0.01%; Bimatoprost 0.03%

Open Angle Glaucoma, or Ocular Hypertension Clinical Trial using Beta-blocker monotherapy; Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

Alcon Research - Recruiting 18 years or older.
- Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTravr in Patients Previously Uncontrolled on a Beta-blocker.
Beta-blocker monotherapy; Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution

Ocular Hypertension Clinical Trial using Sensimed Triggersfishr

Sensimed AG - Recruiting 18 years or older.
- A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfishr in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients.
Sensimed Triggersfishr

Ocular Hypertension, or Primary Open Angle Glaucoma Clinical Trial using VISION5 Product

ForSight Vision5, Inc. - Recruiting 18 years or older.
- A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension.
VISION5 Product

Open-Angle Glaucoma, or Ocular Hypertension Clinical Trial using Brinzolamide 1 %/Brimonidine 0.2% ophthalmic suspension; Timolol Maleate 0.5%

Alcon Research - Recruiting 18 years or older.
- Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination Therapy.
Brinzolamide 1 %/Brimonidine 0.2% ophthalmic suspension; Timolol Maleate 0.5%

Open Angle Glaucoma, or Ocular Hypertension Clinical Trial using laser trabeculoplasty

Santa Clara Valley Health & Hospital System - Recruiting 18 years or older.
- Prospective Evaluation of the Efficacy of Pascal Trabeculoplasty: A Pilot Study.
laser trabeculoplasty

Glaucoma, or Ocular Hypertension Clinical Trial using brimonidine 0.1%; Apraclonidine 0.5%

Walter Reed Army Medical Center - Recruiting 18 years or older.
- Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty.
brimonidine 0.1%; Apraclonidine 0.5%